Abstract
Nowadays, the diagnosis of hepatocellular carcinoma (HCC) is increasingly demanded to imaging techniques. Anyway, imaging cirrhotic patients still remains a challenging issue, since pre-neoplastic hepatocellular lesions, as dysplastic nodules (DNs), may frequently mimic small neoplasms. Differently from other imaging modalities, magnetic resonance (MR) can give an accurate evaluation of both intracellular and vascular changes occurring during the carcinogenetic pathway from dysplasia to full malignancy. Both DNs and HCC may in fact show a large variety of signal intensities, strictly reflecting nodules’ characteristics, such as lesion architecture, grading, stromal components, as well as intracellular contents. In these last years, the introduction of dedicated contrast media has increased MR diagnostic efficacy, permitting to explore both vascular as well as the pathological changes occurring in the biliary and reticuloendothelial systems during the carcinogenetic process. MR performed with tissue specific contrast agents (hepatobiliary and reticulo-endothelial) may thus give an insight on this “gray area”, in whom significant histological changes are already present without an evident nodule arterial supply. This peculiar MR prerogative permits to give predictive information about the evolution trend in a cirrhotic parenchyma and to identify patients at high risk for developing carcinoma who would benefit from well-timed treatments.
Similar content being viewed by others
References
Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530
MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone
Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466
Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71
Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681
Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578
Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809
Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72
Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89
Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792
Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172
Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141
Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748
Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276
Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199
Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134
Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394
Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69
Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566
Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488
Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178
International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664
Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512
Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519
Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236
Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210
Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676
Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805
Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693
Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bartolozzi, C., Battaglia, V. & Bozzi, E. Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36, 290–299 (2011). https://doi.org/10.1007/s00261-011-9687-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-011-9687-z